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Abstract
CD40–CD154 interaction is an important mediator of
inflammation and has been implicated in T helper type 1-
mediated autoimmune diseases including rheumatoid arthritis
(RA). Linkage studies have shown association of markers in the
proximity of the CD154  gene. In the present work we
investigated whether specific allele variants of the microsatellite
in the 3' UTR of the CD154 gene might modulate the risk of RA.
The study, in a case-control setting, included 189 patients and
150 healthy controls from the Canary Islands, Spain. The
24CAs allele was less represented in female patients than in
controls (0.444 in controls versus 0.307 in patients, P = 0.006,
odds ratio (OR) 0.556, 95% confidence interval (CI) 0.372 to
0.831) but not in males (0.414 versus 0.408), and only when
homozygous (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77). We
also verified that CD154 association with RA was independent
of human leukocyte antigen (HLA) phenotype. A further
functional study showed that after stimulation anti-CD3, CD154
mRNA was more stable in CD4+ T lymphocytes from patients
with RA bearing the 24CAs allele (mRNA half-life 208 minutes)
than in patients without the 24CAs allele (109 minutes, P =
0.009). However, a lower percentage of CD154+CD4+  T
lymphocytes was seen in freshly isolated peripheral blood
mononuclear cells from patients carrying 24CAs alleles (mean
4.28 versus 8.12; P = 0.033), and also in CD4+ T lymphocytes
stimulated with anti-CD3 (median 29.40 versus 47.60; P  =
0.025). These results were concordant with the smaller
amounts of CD154 mRNA isolated from stimulated T
lymphocytes with 24CAs  alleles. The CD154  microsatellite
therefore seems to affect the expression of the gene in a
complex manner that implies not only mRNA stability. These
data suggest that the CD154 microsatellite contributes to the
regulation of mRNA and protein expression, although further
studies will be necessary to elucidate its role in disease
predisposition.
Introduction
Rheumatoid arthritis (RA) is a chronic relapsing inflammatory
condition of unknown etiology [1]. The disease is character-
ized by persistent inflammatory synovitis leading to joint
destruction and is sometimes associated with systemic
involvement [2]. Clinical expression of the disease ranges from
ActD = actinomycin D; APC = antigen-presenting cell; BrdU = bromodeoxyuridine; CI = confidence interval; FITC = fluorescein isothiocyanate; HLA 
= human leukocyte antigen; IL = interleukin; mAb = monoclonal antibody; MFI = mean fluorescence intensity; MHC = major histocompatibility com-
plex; NF = nuclear factor; OR = odds ratio; PBMCs = peripheral blood mononuclear cells; PCR = polymerase chain reaction; PHA = phytohemag-
glutinin; RA = rheumatoid arthritis; SSO = sequence-specific oligonucleotides; TCR = T-cell antigen receptor; Th = T helper type; UTR = untranslated 
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a mild, non-deforming arthropathy with little long-term disabil-
ity, to severe, incapacitating, deforming arthritis, which may be
refractory to conventional disease-modifying agents [3].
Because early prescription of a disease-modifying anti-rheu-
matic drug may be more effective in controlling severe dis-
ease, early diagnosis and prediction of severity are important
[4,5]. The identification of markers associated with suscepti-
bility to or severity of RA is therefore currently an important
task.
Twin and family studies provide evidence to support the
involvement of both genetic and environmental factors in the
etiopathogenesis of RA [6,7]. Epidemiological studies show
an important genetic background in RA, with the major histo-
compatibility complex (MHC) region showing the strongest
association with disease predisposition, although the contri-
bution of the human leukocyte antigen (HLA) genes has been
estimated to be no more than 30 to 50% to the total genetic
background [8]. Thus, several other genes outside the MHC
locus are likely to be involved, probably each contributing a
small amount to the genetic predisposition to RA [7]. Recent
findings from linkage studies have drawn attention to several
regions that probably contain candidate genes, namely 1p, 5q,
8p, 12, 13, 18q, 21q and the X chromosome [9-15], for which
association studies are needed.
It is believed that the pathology and etiology of RA involve
abnormal presentation of self antigen(s) by antigen-presenting
cells (APCs) and the activation of autoreactive T cells [16].
Several costimulatory molecules are involved during interac-
tions between APCs and T cells, namely CD40 and CD40 lig-
and (CD154), which are required for the amplification of the
inflammatory response [16]. In RA, T cells expressing CD40
ligand infiltrate the synovial fluid and interact with fibroblasts
expressing CD40, which induces fibroblast proliferation [17],
increased recruitment of inflammatory cells [18], and the pro-
duction of tumor necrosis factor-α [19]. In addition, the pro-
duction of IL-12 by synovial fluid macrophages, which is
required for the initiation of T helper type 1 (Th1) cell
responses, is regulated by the CD40–CD154 interaction [20].
Because RA is mediated by Th1 cells, CD40–CD154 interac-
tion may be an important pathogenic pathway [21]. Indeed,
CD4+ T cells from patients with RA have an increased expres-
sion of CD154 [21-24] that is still observed 5 to 12 years after
disease onset, indicating augmented and prolonged activation
of T cells.
The  CD154  gene is located on the X chromosome and
belongs to the tumor necrosis factor gene family [25]. It con-
tains a dinucleotide repeat of cytosine-adenine (CA) in the 3'
UTR that because of its location may have some bearing on
the regulation of gene expression. Although CD154 is regu-
lated both temporally and with respect to the cell type, the
underlying mechanisms responsible for this control have not
yet been completely elucidated. CD154 gene transcription is
induced by TCR signaling and expression is enhanced in
response to costimulatory signals. Transcriptional regulation
seems to be dependent on NF-AT and NF-κB binding sites
located in the promoter region [26]. Binding sites for AP-1 and
a CD28 response element have also been described [27], and
a NF-κB binding site with enhancer activity has been found
downstream of the poly(A) signal site [28]. In addition to tran-
scriptional regulation, it has been shown that post-transcrip-
tional regulation also has a crucial role in modulating the
expression of the CD154 gene. As with other cytokine genes,
the 3' UTR of the CD154 mRNA contains binding sites for
RNA–protein complexes that are responsible for the lability of
the mRNA. It has been found that the mRNA decay rate can
be specifically modified in some situations, and the protein
complexes involved in this regulation are being characterized
[29-31]. It has been proposed that a putative stability complex
binds specifically to a highly pyrimidine-rich region in the 3'
UTR, and this complex seems to be directly involved in regu-
lating the variable decay rate of CD154 mRNA during T cell
activation [32].
Allele distribution for the dinucleotide-repeat polymorphism
located in the 3' UTR of the CD154 gene has previously been
investigated [33,34]. Allele variants of this polymorphism have
been found to be associated with RA in a subgroup of German
patients [33] and with systemic lupus erythematosus in Span-
iards [35] but not with multiple sclerosis in Nordic patients
[36]. The aim of the present work was to study whether spe-
cific allele variants of this gene might modulate the risk of RA
in Spaniards from the Canary Islands. We also investigated
the influence of the allele variants of CD154 on mRNA and
protein expression in peripheral-blood T cells from patients
with RA.
Materials and methods
Patients and controls
The study used a case-control design to compare patients and
controls. A total of 189 patients diagnosed with RA according
to the American College of Rheumatology criteria were
enrolled at the Rheumatology Unit at the Dr Negrin General
Hospital from Gran Canaria (Canary Islands, Spain). The
median age at onset of RA was 45 years (interquartile range
27 to 63 years) and the median disease duration was 13 years
(interquartile range 2 to 24); 74% of the patients with RA were
female, 78% were positive for rheumatoid factor, 80% had
demonstrated erosions, and 31% presented extra-articular
manifestations. All had received antimalarials or disease-mod-
ifying anti-rheumatic drugs. Control subjects (150 in all;
namely 70 males and 80 females) matched by age and geog-
raphy and with no history of inflammatory arthritis were
recruited. All participants gave their written informed consent.
Samples
Peripheral blood was obtained from patients and controls, and
genomic DNA was extracted by digestion with proteinase KAvailable online http://arthritis-research.com/content/9/5/R89
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and extraction with phenol/chloroform [37] (Sigma-Aldrich, St
Louis, MO, USA). Peripheral blood mononuclear cells
(PBMCs) were obtained by density gradient centrifugation
with Lymphocytes Isolation Solution (Comercial Rafer SL,
Zaragoza, Spain).
CD154 microsatellite typing
A segment of the 3' UTR of the CD154 gene containing the
microsatellite was amplified by PCR, and the amplification
products were resolved over denaturing polyacrylamide gels
as described previously [34]. Allele assignment was per-
formed by densitometry with the Quantity One® Software (Bio-
Rad Laboratories, Hercules, CA, USA). The length of the
amplified fragment was estimated by reference to the stand-
ards used as internal ladder, and the number of repeats was
calculated from the published sequence (GenBank accession
number D31797). In 10 samples genotype assignments were
confirmed with an ABIPRISM 3730 system (Applied Biosys-
tems, Foster City, CA, USA).
HLA typing
HLA class II (DRB1 and DQB1) alleles were studied by PCR
and sequence-specific oligonucleotides hybridization (PCR-
SSO) using LIFEMATCH™ HLA-SSO DNA Typing kits
(Orchid Diagnostics, Stamford, CT, USA), in accordance with
the manufacturer's instructions.
Cell cultures
PBMCs were cultured at 37°C in a humidified 5% CO2 atmos-
phere in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 100 units/ml penicillin, 100 μg/
ml streptomycin and 2 mM L-glutamine (all from Gibco, Life
Technologies Inc., Rockville, MD, USA). T lymphocytes were
expanded in vitro by culturing PBMCs at 2 × 105 cells/ml in
six-well culture plates (Costar, Cambridge, MA, USA) with 5
μg/ml phytohemagglutinin (PHA; Difco Laboratories, Detroit,
MI, USA), 62.5 ng/ml anti-CD28 soluble mAb (Kolt-2;
Menarini, Badalona, Spain), and 50 units/ml recombinant
human IL-2 (Proleukin®; Chiron BV, Amsterdam, Holland).
After a week, more than 95% of the cells in the culture were
CD3+ resting T lymphocytes, as confirmed by flow cytometry.
For stimulation of the PBMCs or expanded T cells with anti-
CD3 mAb, 24-well culture plates (Costar) were coated over-
night at 4°C with 50 μg/ml anti-CD3 mAb (Orthoclone
OKT®3; Cilag AG Int., Zug, Switzerland) in 50 mM Tris-HCl
pH 9.5. After incubation overnight, coating solutions were
removed and plates were washed gently with RPMI 1640
medium to remove unbound mAb. Cells were cultured at 5 ×
105 cells/ml on anti-CD3 coated plates with 62.5 ng/ml anti-
CD28 soluble mAb for 6, 24, 48, 72, or 92 hours, depending
on the assay.
mRNA decay assays
Expanded T cells, once they were resting, were restimulated
with anti-CD3 plus anti-CD28 for 6 or 24 hours as mentioned
above. Then, 10 μg/ml actinomycin D (ActD; Sigma-Aldrich),
a transcriptional inhibitor, was added to the culture and aliq-
uots of cells were collected at different time points for RNA
extraction. Total RNA was isolated by the guanidinium thiocy-
anate method by using the Trizol reagent (Gibco) [38] and
transcribed to cDNA with AMV reverse transcriptase (Roche
Diagnostics, Gmbh, Mannheim, Germany), in accordance with
the manufacturer's instructions. CD154 mRNA was measured
by using a quantitative competitive PCR kit for human CD154
(Maxim Bio, San Francisco, CA, USA), in accordance with the
manufacturer's instructions. Then, 10 μl of each reaction was
subjected to electrophoresis on 2% NuSieve 3:1 agarose gels
(Cambrex Bio Science Rockland, Rockland, MA, USA), and
revealed by staining with ethidium bromide (Sigma-Aldrich).
PCR products were quantified by using the Quantity One
Software with reference to the standard from the kit. In this
technique, serial dilutions of known quantities of PCR compet-
itor are added to PCR reactions containing a constant amount
of target cDNA. The molar ratio of PCR and competitor
remains constant during the reaction, so the initial amount of
target cDNA molecules can be calculated from the known
number of competitor molecules added to the reaction as
[(moles of target CD154 RNA) × (6 × 1023 molecules per
mole) × (dilution factor of test RNA)]/(μg of total RNA). The
number of CD154 mRNA molecules, quantified as indicated
above, was then corrected for the proportion of CD4+ cells in
each sample and expressed as molecules per μg of total RNA
in CD4+  T lymphocytes, assuming equal RNA content
between T cell subtypes. For the determination of mRNA half-
lives (t1/2), fractions of CD154 mRNA remaining after the addi-
tion of ActD were plotted against time after ActD addition.
After exponential adjustment of curves, mRNA half-lives were
calculated as the time in which the fraction of mRNA remaining
decreased to 50% of the initial amount.
CD154 surface expression
Freshly isolated PBMCs or stimulated T cell suspensions were
washed and stained with anti-human CD45, CD3, CD14,
CD4, CD69, CD25, and CD154 mAbs (all from BD Bio-
sciences, San Jose, CA, USA). Labeled cells were then ana-
lyzed in a FACSort flow cytometer with the CellQuest®
software (BD Immunocytometry Systems, San Jose, CA,
USA). The percentage of CD154-positive cells was calculated
by subtracting overlaid CD154 and isotype control (Ig) histo-
grams. Mean fluorescence intensity (MFI) was quantified on a
linear scale as the ratio of the geometric mean of the CD154-
phycoerythrin antibodies against the irrelevant anti-mouse-
IgG-phycoerythrin antibodies of total CD4+ T cells.
Apoptosis assays
Apoptotic cells in culture were detected by staining with fluo-
rescein isothiocyanate (FITC)-labeled annexin-V (Roche Diag-Arthritis Research & Therapy    Vol 9 No 5    Martin-Donaire et al.
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nostics) and propidium iodide (Sigma-Aldrich). After 15
minutes in the dark, cells were analyzed by flow cytometry. Cell
viability was measured as the percentage of cells that were
negative for both annexin-V and propidium iodide.
Proliferation assays
PBMCs were stimulated with anti-CD3 plus anti-CD28 for
three days, subsequently pulsed with 60 μM
bromodeoxyuridine (BrdU) (Sigma-Aldrich), and harvested 18
hours later. The incorporation of BrdU was measured by stain-
ing with an FITC-conjugated anti-BrdU antibody (BD Bio-
sciences) and analyzed by flow cytometry.
Statistical analysis
Allele and genotype frequencies and carrier rates were calcu-
lated in patients with RA and in controls, and no deviations
from Hardy–Weinberg equilibrium in controls were confirmed
by comparison of observed and expected genotype frequen-
cies [39]. Differences in allele/genotype frequencies between
patients and healthy control subjects were tested by the χ2
method, using the Yates or Bonferroni correction or Fisher's
exact test when appropriate. The strength of association
between RA and alleles of CD154, DRB1 and DQB1 was
estimated by using odds ratios (ORs) and the exact limits of
the 95% confidence intervals (CIs). Estimation of the statisti-
cal power for the comparison of allele frequencies was per-
formed with the STPLAN software. The arcsin approximation
of the binomial distributions of allele frequencies was used
with a two-sided test and with α fixed at 0.05. To examine
interactions between variables associated with RA we con-
ducted a multivariate analysis with a binary logistic regression
model. Surface expression levels of CD154  mRNA and
CD154 protein were compared by using the non-parametric
Mann–Whitney test. The statistical package SSPS for Win-
dows v. 10 (SSPS Inc., Chicago, IL, USA) was used. P < 0.05
was considered statistically significant.
Results
CD154 microsatellite is associated with RA in females
Overall, allele frequencies (Additional file 1) did not differ
between patients and controls after applying the Bonferroni
correction to the χ2 test (pc = 0.34). However, comparison of
the frequencies of each allele between patients and controls
showed differences for the 24CAs allele (0.32 versus 0.44; P
= 0.009; OR 0.62, 95% CI 0.44 to 0.88; power 0.70) and the
26CAs allele (0.088 versus 0.030; P = 0.014; OR 2.96, 95%
CI 1.27 to 6.91; power 0.80). Because CD154 is located on
the X chromosome, we compared allele frequencies between
patients and controls in males and females separately. We
observed statistical differences in the 24CAs allele frequency
in females (0.44 in healthy controls versus 0.31 in patients; P
= 0.006; OR 0.56, 95% CI 0.37 to 0.83; power 0.82) but not
in males (0.41 versus 0.41). Similarly, differences were found
in the 26CAs allele in females (0.03 in healthy controls versus
0.09 in patients; P = 0.033; OR 3.04, 95% CI 1.14 to 8.10;
power 0.78) but not in males (0.03 versus 0.06). These data
suggested a possible disease-protective role for the 24CAs
variant in females. However, for the 26CAs allele, its contribu-
tion to disease predisposition does not seem to be relevant
because of the low incidence in both patients and controls.
Next, we studied genotype frequencies in females, and we
found a lower frequency of the 24CAs/24CAs homozygous
genotype (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77) in
patients with RA than in healthy controls (Figure 1a). We then
classified females as being carriers of two (24/24), one (24/X)
or zero (X/X) 24CAs alleles by comparing these genotype fre-
quencies. As can be seen in Figure 1b, RA females bearing
Figure 1
Genotype frequencies of the CD154 microsatellite in healthy females  and those with rheumatoid arthritis Genotype frequencies of the CD154 microsatellite in healthy females 
and those with rheumatoid arthritis. (a) Seventy-nine female patients 
with rheumatoid arthritis (RA) were compared with 56 healthy females 
(Pc = 0.483). Genotypes represented fewer than five times are not 
included. *P = 0.012. (b) The frequency for carriers of two (24/24), 
one (24/X) or zero (X/X) alleles of 24CAs, where X represents any 
allele different from 24CAs. One hundred and forty female patients with 
RA were compared with 80 healthy females (Pc = 0.026). **P = 0.042, 
***P = 0.012.Available online http://arthritis-research.com/content/9/5/R89
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24CAs/24CAs were less frequent (P = 0.012), whereas X/X
cases were more frequent (P = 0.042) than in healthy con-
trols, indicating that the 24CAs allele seems to protect from
RA when homozygous.
Association of CD154 with RA is independent of HLA-
DRB1 and HLA-DQB1
Epidemiological studies show a strong association of MHC
region with disease predisposition, being related to the
presence of 'shared epitopes' of HLA-DRB1, which includes
the DRB1*04 and DRB1*01 alleles. To confirm whether the
observed 'CD154 association' could be influenced by HLA
phenotype, we typed DRB1 and DQB1 genes in our patients
and controls by low-resolution PCR-SSO techniques. Patients
with RA from the Canary Islands showed higher allele frequen-
cies of DR4 (0.27 versus 0.12 in controls; P < 0.0005; OR
2.68, 95% CI 1.65 to 4.35) and DQ3 (0.39 versus 0.27 in
controls; P = 0.005; OR 1.74, 95% CI 1.20 to 2.54), confirm-
ing the association of these variants with RA previously
described in Spaniards [40,41].
Next, we analyzed the distribution of pairs of variables in
patient and control groups in contingency tables to test
whether the association of any variable with RA depended on
the presence of any other variable. This analysis revealed that
the association of DQ3 with RA was dependent on DR4, as
expected from the linkage of both genes (data not shown) and
that CD154  was associated with RA independently of the
presence of DR4 (Table 1). The influence of sex in the associ-
ated variables was analyzed by using a multivariate binary
logistic regression model. The final model included DR4,
24CAs and sex as independent variables, and disease as the
dependent variable. As can be seen in Table 2, the association
of CD154-24CAs, but not DR4, with RA is affected by sex.
CD154 microsatellite influences mRNA stability in T 
lymphocytes
Because of the proximity of the CD154 microsatellite to sites
regulating mRNA stability [30,32], we considered studying
whether this polymorphism could affect the CD154 mRNA
half-life. This gene is located on the X chromosome, so we
selected homozygotic patients with RA to assign the pheno-
type to a single allele; these individuals were then stratified by
genotype. It is known that activation of peripheral T lym-
phocytes in patients with RA can fluctuate, affecting to the
degree of apoptosis or response to mitogens in vitro. To avoid
this heterogeneity, we first used PHA, anti-CD28 and IL-2 to
stimulate PBMCs from 20 patients. After 1 week in culture,
homogeneous cellular populations were obtained with more
than 95% of resting CD3+ lymphocytes, as confirmed by
CD69 staining. The CD4/CD8 ratio of these cells did not differ
between 24CAs and non-24CAs  patients (2.02 and 1.82,
respectively; P = 0.037). Anti-CD3 stimulation for 24 hours or
more has been shown to specifically stabilize the normally
unstable CD154 mRNA, augmenting its half-life notably [29].
We therefore stimulated the previously expanded T cells with
anti-CD3 and anti-CD28 for 6 or 24 hours to analyze the effect
of the microsatellite in both situations. After that, cells were
Table 1
Distribution of 24CAs carriers among DR4+ and DR4- patients with RA and healthy controls
Allele DR4- DR4+
RA (n = 98) Healthy controls 
(n = 77)
P RA (n = 91) Healthy controls 
(n = 22)
P
Non-24CAs 51 (52) 31 (40.3) 0.121 45 (49.5) 11 (50) 0.963
24CAs 47 (48) 46 (50.5) 46 (59.7) 11 (50)
n, number of samples analyzed. Results in parentheses are percentages.
Table 2
Binary logistic regression model showing influence of sex on CD154 gene association with RA
Parameter Coefficient Standard error OR (95% CI) Pa
Constant -0.242 0.227
DR4 1.109 0.289 3.03 (1.72–5.34) <0.001
Sex 1.386 0.368 4.00 (1.95–8.22) <0.001
CD154-24CAs by sex -0.946 0.362 0.39 (0.19–0.79) 0.009
OR, odds ratio; CI, confidence interval. ap value based on Wald statistic.Arthritis Research & Therapy    Vol 9 No 5    Martin-Donaire et al.
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treated with the transcriptional inhibitor ActD, and the decay
of CD154 mRNA was determined by quantitative competitive
reverse transcriptase-mediated PCR.
After 6 hours of stimulation, we found statistically significant
differences in the half-life of CD154 mRNA between 24CAs
(t1/2 49.7 ± 17.4 minutes (mean ± SD)) and non-24CAs alle-
les (32.2 ± 10.8 minutes; P = 0.005) (Figure 2a). After 24
hours of stimulation, there was a clear mRNA stabilization in
both groups of patients (fourfold increase in the 24CAs mRNA
t1/2  (208 ± 115 minutes) in comparison with a threefold
increase in non-24CAs mRNA t1/2 (109 ± 39 minutes); P =
0.009) (Figure 2a). In contrast with what we expected, the
half-life of the 24CAs mRNAs was higher than that of the rest
of the alleles after 6 and 24 hours of anti-CD3 stimulation. As
shown in Figure 2a, scattering of the data in the non-24CAs
group was similar to that in the 24CAs group. This indicated
that the functional behavior of the samples included in the non-
24CAs group, in spite of the inclusion of several different alle-
les, was as homogeneous as that in the 24CAs samples, vali-
dating our stratification of patients by 24CAs allele. A similar
pattern was also observed in healthy individuals, although a
statistical comparison was not performed for healthy samples
because of the low sample numbers (Figure 2a).
However, if the number of molecules was compared instead of
mRNA decay, the total number of CD154 mRNA molecules in
CD4 T lymphocytes after 6 hours of stimulation with anti-CD3
plus anti-CD28 was significantly lower in patients with 24CAs
(6.181 ± 2.908 molecules (mean ± SD) of CD154 mRNA per
μg of total RNA in CD4 T lymphocytes) than in those with non-
24CAs  alleles (21.254 ± 19.994; P  < 0.05). The same
occurred after 24 hours of stimulation with anti-CD3 plus anti-
CD28 (3.461 ± 2.277 molecules of CD154 mRNA per μg of
total RNA in CD4 T lymphocytes, versus 7.009 ± 8.637 in
non-24CAs; P < 0.05; Figure 2b). In both cases these initial
differences were shortened along the time in culture after the
addition of ActD (probably as a result of the greater stability of
the 24CAs mRNA).
CD154 microsatellite influences surface protein 
expression in T lymphocytes
We next tried to assess whether the CD154 microsatellite
could affect protein expression in RA T lymphocytes, as we
had previously described in healthy donors [35]. First, we
compared the expression of several surface markers in freshly
isolated PBMCs from patients with RA who were homozygous
for  24CAs  or non-24CAs  alleles. As shown in Table 3,
patients with 24CAs alleles displayed a higher percentage of
CD19+  B lymphocytes (P  = 0.018) and of activated
CD25+CD4+ T lymphocytes (P = 0.036) but, surprisingly, a
lower percentage of CD154+CD4+  T lymphocytes (P  =
0.033). The MFI was also higher in patients with RA who were
homozygous for non-24CAs alleles (4.44 ± 1.02 versus 3.22
± 1.10), although differences did not reach statistical signifi-
cance (data not shown).
Figure 2
Expression of CD154 mRNA in T lymphocytes according to CD154 genotype Expression of CD154 mRNA in T lymphocytes according to CD154 genotype. T lymphocytes from patients with rheumatoid arthritis (RA; 24CAs 
group, n = 9; non-24CAs group, n = 11) and controls (24CAs group, n = 3; non-24CAs group, n = 3), obtained after in vitro expansion of periph-
eral blood mononuclear cells, were stimulated for 6 or 24 hours with anti-CD3 plus anti-CD28; after this, mRNA decay assays were performed as 
indicated in the Materials and methods section. (a) mRNA half-life, t1/2, in T lymphocytes. (b) mRNA molecules per μg of total RNA in CD4+ T lym-
phocytes. *P < 0.05, **P < 0.005, comparing the 24CAs group with the non-24CAs group.
Table 3
Basal expression of surface markers in PBMCs of patients with 
RA according to CD154 genotype
Surface 
markers
24CAs
(n = 13)
Non-24CAs
(n = 15)
P
CD16/CD56a 16.07 ± 10.78 12.38 ± 10.24 n.s.
CD19a 6.42 ± 3.12 4.17 ± 3.01 0.018
CD3/CD8a 17.24 ± 7.66 22.37 ± 6.67 n.s.
CD3/CD4a 44.40 ± 14.79 41.22 ± 13.11 n.s.
CD4/CD69b 14.09 ± 19.02 7.48 ± 10.25 n.s.
CD4/CD25b 59.59 ± 18.04 41.19 ± 22.84 0.036
CD4/CD154b 4.28 ± 3.81 8.12 ± 5.73 0.033
Results are means ± SD for cells expressing the indicated surface 
markers, quantified by flow cytometry. Differences were evaluated by 
the Mann–Whitney U test. n, number of samples analyzed; n.s., non 
significant; PBMCs, peripheral blood mononuclear cells. aReferred to 
total lymphocytes; breferred to total CD4+ lymphocytes.Available online http://arthritis-research.com/content/9/5/R89
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To assess the influence of the microsatellite in the kinetics of
surface expression of the CD154 protein, PBMCs from both
groups of homozygous patients with RA were stimulated with
anti-CD3 plus anti-CD28 for 24 hours or more, to allow mRNA
stabilization and thus favor protein surface expression. Initially,
we verified that there were no differences between groups in
the numbers of apoptotic or proliferating cells, or of
contaminating monocytes (data not shown), and the activation
of anti-CD3-stimulated lymphocytes was confirmed in all sam-
ples by staining for CD69 and CD25 and by flow cytometry
analysis (data not shown). We observed an increase in the
percentage of CD154+CD4+ lymphocytes, reaching a maxi-
mum at 48 hours in both groups, but it was lower in patients
with  24CAs  alleles than in those with non-24CAs  alleles
(median 29.4% of CD154+CD4+ lymphocytes versus 47.6%)
(P = 0.025; Figure 3). Again, MFIs calculated as the ratio
GeoMean CD154/GeoMean Ig were higher in patients with
non-24CAs alleles but did not reach statistical significance
(2.92 ± 1.09 versus 2.37 ± 0.83; P = 0.098).
Discussion
In the present study we describe the association of the micro-
satellite in the 3' UTR of the CD154 gene with RA in females
from the Canary Islands. The 24CAs allele is less represented
Figure 3
Kinetics of surface expression of CD154 in stimulated T lymphocytes (a) CD154 kinetic expression in CD4+ T lymphocytes from patients with rheu- matoid arthritis (RA) after stimulation with anti-CD3/anti-CD28, according to CD154 genotype Kinetics of surface expression of CD154 in stimulated T lymphocytes (a) CD154 kinetic expression in CD4+ T lymphocytes from patients with rheu-
matoid arthritis (RA) after stimulation with anti-CD3/anti-CD28, according to CD154 genotype. Peripheral blood mononuclear cells from patients 
with RA (24CAs group, n = 19; non-24CAs group, n = 16) were stimulated in vitro with anti-CD3/anti-CD28 for 24, 48, 72, and 92 hours. After 
this, the surface expression of CD154 was measured by flow cytometry. The graph shows the median percentage of CD154 expression in CD4+ T 
lymphocytes from each group at the indicated times. *P = 0.046, comparing the 24CAs group with the non-24CAs group. (b) Cytometry histo-
grams showing CD154 staining (thick line) compared with non-specific staining (isotype control mAb, thin line) in CD4+ T lymphocytes from repre-
sentative patients with RA (upper panel, 24CAs; lower panels, non-24CAs), after 24 hours (left panels) and 48 hours (right panels) of stimulation 
with anti-CD3/anti-CD28. PE, phycoerythrin.Arthritis Research & Therapy    Vol 9 No 5    Martin-Donaire et al.
Page 8 of 11
(page number not for citation purposes)
in patients than in controls, the difference being significant in
women but not in men, and this gene variant protects from RA
when homozygous. Different immunogenetic associations in
male and female patients with RA have been described previ-
ously [42-46], although the mechanism underlying these dif-
ferences is not fully understood. One possible explanation of
these findings is that RA in males and females might be partly
diverging disease entities, as proposed by Weyand and col-
leagues [47] or, alternatively, might result from the existence of
differential hormonal influences. It is well known that RA is
three times more frequent in women than in men, and many
patients experience a clinical remission during pregnancy.
However, it remains to be elucidated how hormonal differ-
ences might account for sex differences in CD154 association
with disease susceptibility. In line with this, recent data have
shown that CD154 expression could be modified by hor-
mones such as estrogens [48] and prolactin [49].
We also demonstrate that, although HLA-DR4 and HLA-DQ3
is associated with RA in the Canary Islands population, in
agreement with previous studies in Spaniards [41,44],
CD154 association against RA is independent of HLA pheno-
type. These results differ from those previously obtained in
Germans by Gomolka and colleagues [33], who described
that the 21CAs allele is a risk factor for patients with RA who
are DR4-DR1-. Different allele frequencies between northern
and southern Europe have been described for a variety of
gene polymorphisms and probably contribute to the observed
discrepancy, although there are other methodological reasons
that also could explain the disparity of the results. Compari-
sons in the German population were not performed separately
in men and women, and phenotype rather allele or genotype
frequencies were used. Our data arranged in that way result in
a similar overall distribution of phenotype frequencies to that
reported by Gomolka and colleagues in both controls and
patients with RA. Similarly, in our cohort 18% of DR4-DR1-
patients with RA bear a 21CAs allele, compared with only
0.5% of DR4- DR1- in controls. However, we excluded the
analysis of minor alleles because the small number of individu-
als with those alleles did not permit reliable statistical compar-
isons to be made.
We wished to see whether the association that we had found
between the CD154 microsatellite and predisposition to RA
was sustained by the differential expression of the gene variant
associated with RA. Regulation of mRNA stability is important
in controlling the expression of this gene, and the microsatel-
lite lies close to sites of binding of protein complexes that mod-
ulate mRNA stability [29]; CA repeats have been shown to
have a direct influence on mRNA stability [50], as well as on
other events of gene expression [51-53]. We checked
whether 24CAs alleles displayed different behaviors in rela-
tion to mRNA decay rates and compared the 24CAs mRNA
with the other alleles. In agreement with previous studies
[29,54], we confirmed that CD154 mRNA was more labile
after 6 hours of stimulation with anti-CD3 than after 24 hours,
but mRNAs with 24CAs alleles had greater half-lives than the
mRNAs from the other alleles after 6 and 24 hours of stimula-
tion with anti-CD3.
Regarding protein expression, non-24CAs  CD4 T cells
expressed more CD154 after 48 hours of stimulation with anti-
CD3/anti-CD28. Because staining for CD154 produced
single-peaked histograms overlapping the negative control
histograms, it is difficult to provide a precise description of
CD154 distribution across CD4 T cells in terms of the per-
centage of positive cells and the mean MFI of the positive pop-
ulation. Staining of a Jurkat cell line with the same antibody
resulted in two peaks, with a clear separation of CD154-posi-
tive and CD154-negative subpopulations. Dilution of the anti-
CD154 antibody to mimic low CD154 expression changed
the shape of the histogram to form a single peak overlaid with
the control peak. In this situation, the percentages of positive
cells calculated by subtracting positive and negative histo-
grams did not reflect the true fraction of positive cells and
changes according to the quantity of antibody added (data not
shown). Thus, the dimly stained CD4 T cells from patients with
RA in our 'in vitro' assay seem to be reflecting a low density of
CD154 on the surface, and the percentages of positive cells
obtained probably do not reflect the true CD154-positive frac-
tion of cells but still provide a rough measure of CD154 quan-
tity in the CD4 T cell population.
Statistical analysis showed significant differences in the per-
centages of CD154+ cells but not in the MFIs. However, data
on these two results look similar and both seem to provide an
expression of the higher content of CD154 in non-24CAs
CD4 T cells. Ultimately, what is relevant is that this differential
CD154 expression may be meaningful 'in vivo', affecting the
response of the immune system to autoantigens, and hence
the probability of developing autoimmunity. In this regard, it is
interesting that a higher CD154 protein expression in people
with the non-24CAs allele has been consistently found in a
variety of situations with similar differences between people
with 24CAs and non-24CAs genotypes (median percentage
of CD154+ cells, 24CAs/median percentage of CD154+ cells,
non-24CAs: 0.64 in freshly isolated PBMCs, 0.62 in anti-
CD3/anti-CD28 stimulated PBMCs, and 0.55 in PBMCs after
1 week of expansion with PHA/anti-CD28), supporting the
idea that CD154 microsatellite alleles influence the expression
of this gene after TCR engagement. Nevertheless, it is impor-
tant to note that this higher CD154 expression in non-24CAs
refers to average values, and individual percentages and MFIs
substantially overlap between 24CAs and non-24CAs. We
lack several replications of a single individual to estimate the
variation inherent in the assay, but it is likely that a significant
amount of the scattering in the data is produced by interindi-
vidual variations in several genes other than CD154 that also
influence the expression of this gene after T cell activation.Available online http://arthritis-research.com/content/9/5/R89
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Results in protein expression seem to contrast with results on
mRNA stability. However, there are some concerns about the
comparison of mRNA and protein results because different
sources of cells were used for each experiment. Direct com-
parison of these results should be taken with caution, because
different proportions of T cell subsets could have distinct
kinetic patterns of CD154 expression. Furthermore, times of
stimulation in the analysis of mRNA and protein expression
match at only one time point (24 hours), so these experiments
cannot be paralleled.
Taking the results together, the 24CAs allele, although confer-
ring more stability on its mRNA, finally seems to result in a
lower CD154 protein expression after activation. This means
that the microsatellite alleles are associated not only with
mRNA half-life, which seems plausible because of its location
in the 3' UTR, but with other factors that probably affect the
transcription of the gene and that result in a lower percentage
of T cells expressing this protein on the surface after stimula-
tion of the TCR. Although very speculative, this could be
related to the NF-κB enhancer located near the microsatellite,
which has been shown to have a crucial effect on transcription
of the gene [28]. Changes in the affinity of this NF-κB site
related to allelic variants of the microsatellite could lead to dif-
ferent thresholds for the activation of transcription, which in
turn could lead to different percentages of cells expressing
CD154 when stimulated.
These results therefore seem to agree with the known pattern
of CD154 expression, because it has been shown that the
greatest level of CD154 expression after T cell activation
occurs at a time when the mRNA is being rapidly degraded
and that expression is controlled by both transcriptional mech-
anisms and message stability [54].
More studies will be necessary to confirm the association of
this microsatellite marker with RA, to establish more accurately
whether the association occurs through a direct effect in the
expression of the CD154 gene and, if so, what are the exact
mechanisms by which different alleles lead to a different
expression of the gene.
The present results and our previous data showing CD154
association with systemic lupus erythematosus in Canary
Islanders suggest that CD154 may commonly contribute to
the pathophysiological process and common immunogenetic
mechanisms underlying both autoimmune diseases, thus
being in agreement with the hypothesis of the 'common
genetic origin' of autoimmune diseases [55,56].
Conclusion
In the present study we report the association of the microsat-
ellite in the 3' UTR of CD154 with RA in females from the
Canary Islands. Differences found in mRNA decay according
to  CD154  genotypes suggest that this polymorphism may
contribute to the regulation of mRNA expression, although fur-
ther assays will be necessary to elucidate its role in disease
predisposition. Additional studies from other series of patients
will be required to confirm this genetic association.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TM-D and IL-F designed the study, performed the experiments,
analyzed and discussed the results and prepared the manu-
script. These authors contributed equally to this work, and the
order of authorship is arbitrary. GP-C participated in the
analysis and interpretation of the results and in manuscript
preparation. IR-F, CE, and AN participated in the collection of
clinical data, in the recruitment of patients and in the discus-
sion of results. SR participated in the analysis and
interpretation of the results. FS and MJC performed genotyp-
ing of the control group. AG-S participated in the collection of
samples. JAV contributed to the discussion. PP-A coordinated
the study, participated in its design, oversaw all aspects of the
laboratory work and participated in manuscript writing and dis-
cussion. All authors read and approved the final manuscript.
Additional files
Acknowledgements
We are grateful to the patients with RA, the control individuals, and the 
collaborating clinicians for their participation in this study. We thank C. 
Garcia-Gallego, I. Garcia-Laorden and N. Rebolleda for their help. This 
study was supported by Fundación LAIR (P1310). T.M. was supported 
by a grant of Comunidad de Madrid.
References
1. Decker JL, Malone DG, Haraoui B, Wahl SM, Schrieber L, Klippel
JH, Steinberg AD, Wilder RL: NIH conference. Rheumatoid
arthritis: evolving concepts of pathogenesis and treatment.
Ann Intern Med 1984, 101:810-824.
2. Buckley CD: Why does chronic inflammatory joint disease
persist?  Clin Med 2003, 3:361-366.
3. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smo-
len JS: Early referral recommendation for newly diagnosed
rheumatoid arthritis: evidence based development of a clinical
guide.  Ann Rheum Dis 2002, 61:290-297.
4. Wassmuth R, Wagner U: Prognostic use of human leukocyte
antigen genotyping for rheumatoid arthritis susceptibility, dis-
ease course, and clinical stratification.  Rheum Dis Clin North
Am 2002, 28:17-37.
The following Additional files are available online:
Additional file 1
An Excel containing data on the allelic frequencies of 
CD154 microsatellite in patients and controls.
See http://www.biomedcentral.com/content/
supplementary/ar2288-S1.xlsArthritis Research & Therapy    Vol 9 No 5    Martin-Donaire et al.
Page 10 of 11
(page number not for citation purposes)
5. van der Helm-van Mil AH, Wesoly JZ, Huizinga TW: Understand-
ing the genetic contribution to rheumatoid arthritis.  Curr Opin
Rheumatol 2005, 17:299-304.
6. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho
K, Silman AJ: Characterizing the quantitative genetic contribu-
tion to rheumatoid arthritis using data from twins.  Arthritis
Rheum 2000, 43:30-37.
7. Dieude P, Cornelis F: Genetic basis of rheumatoid arthritis.
Joint Bone Spine 2005, 72:520-526.
8. Silman AJ, Pearson JE: Epidemiology and genetics of rheuma-
toid arthritis.  Arthritis Res 2002, 4(Suppl 3):S265-S272.
9. Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C,
Alves H, Barrera P, de Vries N, Balsa A: New susceptibility locus
for rheumatoid arthritis suggested by a genome-wide linkage
study.  Proc Natl Acad Sci USA 1998, 95:10746-10750.
10. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro
J, Kern M, Criswell LA, Albani S, Nelson JL, et al.: A genomewide
screen in multiplex rheumatoid arthritis families suggests
genetic overlap with other autoimmune diseases.  Am J Hum
Genet 2001, 68:927-936.
11. Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE,
Panayi GS, Lewis CM, Lanchbury JS: Multipoint linkage analysis
of a candidate gene locus in rheumatoid arthritis demon-
strates significant evidence of linkage and association with
the corticotropin-releasing hormone genomic region.  Arthritis
Rheum 2000, 43:1673-1678.
12. MacKay K, Eyre S, Myerscough A, Milicic A, Barton A, Laval S, Bar-
rett J, Lee D, White S, John S, et al.: Whole-genome linkage anal-
ysis of rheumatoid arthritis susceptibility loci in 252 affected
sibling pairs in the United Kingdom.  Arthritis Rheum 2002,
46:632-639.
13. John S, Shephard N, Liu G, Zeggini E, Cao M, Chen W, Vasavda
N, Mills T, Barton A, Hinks A, et al.: Whole-genome scan, in a
complex disease, using 11,245 single-nucleotide polymor-
phisms: comparison with microsatellites.  Am J Hum Genet
2004, 75:54-64.
14. Etzel CJ, Chen WV, Shepard N, Jawaheer D, Cornelis F, Seldin
MF, Gregersen PK, Amos CI: Genome-wide meta-analysis for
rheumatoid arthritis.  Hum Genet 2006, 119:634-641.
15. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH: Genome scan meta-
analysis of rheumatoid arthritis.  Rheumatology 2006,
45:166-170.
16. Aarvak T, Natvig JB: Cell-cell interactions in synovitis: antigen
presenting cells and T cell interaction in rheumatoid arthritis.
Arthritis Res 2001, 3:13-17.
17. Rissoan MC, van KC, Chomarat P, Galibert L, Durand I, Thivolet-
Bejui F, Miossec P, Banchereau J: The functional CD40 antigen
of fibroblasts may contribute to the proliferation of rheumatoid
synovium.  Clin Exp Immunol 1996, 106:481-490.
18. Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS, Park SH,
Choe J, Kim HY: CD40 engagement on synovial fibroblast up-
regulates production of vascular endothelial growth factor.  J
Immunol 2000, 164:5055-5061.
19. Harigai M, Hara M, Nakazawa S, Fukasawa C, Ohta S, Sugiura T,
Inoue K, Kashiwazaki S: Ligation of CD40 induced tumor necro-
sis factor-α in rheumatoid arthritis: a novel mechanism of acti-
vation of synoviocytes.  J Rheumatol 1999, 26:1035-1043.
20. Mottonen M, Isomaki P, Luukkainen R, Lassila O: Regulation of
CD154-induced interleukin-12 production in synovial fluid
macrophages.  Arthritis Res 2002, 4:R9.
21. MacDonald KP, Nishioka Y, Lipsky PE, Thomas R: Functional
CD40 ligand is expressed by T cells in rheumatoid arthritis.  J
Clin Invest 1997, 100:2404-2414.
22. Gotoh H, Kawaguchi Y, Harigai M, Hara M, Saito S, Yamaguchi T,
S h i m a d a  K ,  K a w a m o t o  M ,  T o m a t s u  T ,  K a m a t a n i  N :  Increased
CD40 expression on articular chondrocytes from patients with
rheumatoid arthritis: contribution to production of cytokines
and matrix metalloproteinases.  J Rheumatol 2004,
31:1506-1512.
23. Berner B, Wolf G, Hummel KM, Muller GA, Reuss-Borst MA:
Increased expression of CD40 ligand (CD154) on CD4+ T cells
as a marker of disease activity in rheumatoid arthritis.  Ann
Rheum Dis 2000, 59:190-195.
24. Liu MF, Chao SC, Wang CR, Lei HY: Expression of CD40 and
CD40 ligand among cell populations within rheumatoid syno-
vial compartment.  Autoimmunity 2001, 34:107-113.
25. Gaur U, Aggarwal BB: Regulation of proliferation, survival and
apoptosis by members of the TNF superfamily.  Biochem
Pharmacol 2003, 66:1403-1408.
26. Srahna M, Remacle JE, Annamalai K, Pype S, Huylebroeck D,
Boogaerts MA, Vandenberghe P: NF-κB is involved in the regu-
lation of CD154 (CD40 ligand) expression in primary human T
cells.  Clin Exp Immunol 2001, 125:229-236.
27. Tsytsykova AV, Tsitsikov EN, Geha RS: The CD40L promoter
contains nuclear factor of activated T cells-binding motifs
which require AP-1 binding for activation of transcription.  J
Biol Chem 1996, 271:3763-3770.
28. Schubert LA, Cron RQ, Cleary AM, Brunner M, Song A, Lu LS, Jul-
lien P, Krensky AM, Lewis DB: A T cell-specific enhancer of the
human CD40 ligand gene.  J Biol Chem 2002, 277:7386-7395.
29. Barnhart B, Kosinski PA, Wang Z, Ford GS, Kiledjian M, Covey LR:
Identification of a complex that binds to the CD154 3' untrans-
lated region: implications for a role in message stability during
T cell activation.  J Immunol 2000, 165:4478-4486.
30. Hamilton BJ, Genin A, Cron RQ, Rigby WF: Delineation of a
novel pathway that regulates CD154 (CD40 ligand)
expression.  Mol Cell Biol 2003, 23:510-525.
31. Singh K, Laughlin J, Kosinski PA, Covey LR: Nucleolin is a second
component of the CD154 mRNA stability complex that regu-
lates mRNA turnover in activated T cells.  J Immunol 2004,
173:976-985.
32. Kosinski PA, Laughlin J, Singh K, Covey LR: A complex contain-
ing polypyrimidine tract-binding protein is involved in regulat-
ing the stability of CD40 ligand (CD154) mRNA.  J Immunol
2003, 170:979-988.
33. Gomolka M, Menninger H, Saal JE, Lemmel EM, Albert ED, Niwa
O, Epplen JT, Epplen C: Immunoprinting: various genes are
associated with increased risk to develop rheumatoid arthritis
in different groups of adult patients.  J Mol Med 1995,
73:19-29.
34. Citores MJ, Perez-Aciego P, Rodriguez-Gallego C, Contreras-Mar-
tin B, Garcia-Laorden I, Durantez A: CD154 polymorphism in
Spanish populations. Differences in the allelic distribution
between Canary islanders and Peninsulars.  Eur J
Immunogenet 2000, 27:141-144.
35. Citores MJ, Rua-Figueroa I, Rodriguez-Gallego C, Durantez A, Gar-
cia-Laorden MI, Rodriguez-Lozano C, Rodriguez-Perez JC, Vargas
JA, Perez-Aciego : The dinucleotide repeat polymorphism in
the 3' UTR of the CD154 gene has a functional role on protein
expression and is associated with systemic lupus
erythematosus.  Ann Rheum Dis 2004, 63:310-317.
36. Dai Y, Masterman T, Huang W, Hillert J: Analysis of a CD40 lig-
and dinucleotide microsatellite in multiple sclerosis.  Eur J
Immunogenet 2002, 29:81-85.
37. Blin N, Stafford DW: A general method for isolation of high
molecular weight DNA from eukaryotes.  Nucleic Acids Res
1976, 3:2303-2308.
38. Chomczynski P, Sacchi N: Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform
extraction.  Anal Biochem 1987, 162:156-159.
39. Schneider S: RDaEL. A Software for Population Genetics Data
Analysis. Arlequin ver.2.000 Geneva: Genetics and Biometry Lab-
oratory, University of Geneva. 
40. Yelamos J, Garcia-Lozano JR, Moreno I, Aguilera I, Gonzalez MF,
Garcia A, Nuñez-Roldan A, Sanchez B: Association of HLA-DR4-
Dw15 (DRB1*0405) and DR10 with rheumatoid arthritis in a
Spanish population.  Arthritis Rheum 1993, 36:811-814.
41. Balsa A, Minaur NJ, Pascual-Salcedo D, McCabe C, Balas A, Fid-
dament B, Vicario JL, Cox NL, Martin-Mola E, Hall ND: Class II
MHC antigens in early rheumatoid arthritis in Bath (UK) and
Madrid (Spain).  Rheumatology 2000, 39:844-849.
42. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A: HLA-
DRB1*0401/0404 genotype and rheumatoid arthritis:
increased association in men, young age at onset, and disease
severity.  J Rheumatol 1995, 22:1032-1036.
43. Hajeer A, John S, Ollier WE, Silman AJ, Dawes P, Hassell A, Mat-
tey D, Fryer A, Strange R, Worthington J: Tumor necrosis factor
microsatellite haplotypes are different in male and female
patients with RA.  J Rheumatol 1997, 24:217-219.
44. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A,
Nunez-Roldan A: Complex associations between HLA-DRB1
genes and female rheumatoid arthritis: results from a pro-
spective study.  Hum Immunol 1999, 60:1259-1265.Available online http://arthritis-research.com/content/9/5/R89
Page 11 of 11
(page number not for citation purposes)
45. de VN, Tak PP, Tijssen H, van Riel PL, van de Putte LB: Female
sex increases risk for rheumatoid arthritis only in individuals
encoding low-risk HLA-DRB1 alleles.  Arthritis Rheum 2003,
48:1762-1763.
46. Pierer M, Kaltenhauser S, Arnold S, Wahle M, Baerwald C,
Hantzschel H, Wagner U: Association of PTPN22 1858 single-
nucleotide polymorphism with rheumatoid arthritis in a Ger-
man cohort: higher frequency of the risk allele in male com-
pared to female patients.  Arthritis Res Ther 2006, 8:R75.
47. Weyand CM, Schmidt D, Wagner U, Goronzy JJ: The influence of
sex on the phenotype of rheumatoid arthritis.  Arthritis Rheum
1998, 41:817-822.
48. Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI: Estrogen
increases CD40 ligand expression in T cells from women with
systemic lupus erythematosus.  J Rheumatol 2001,
28:2644-2649.
49. Chavez-Rueda K, Legorreta-Haquet MV, Cervera-Castillo H,
Sanchez L, Jara LJ, Zenteno E, Blanco-Favela F: Prolactine effect
on CD69 and CD154 expression by CD4+ cells from systemic
lupus erythematosus patients.  Clin Exp Rheumatol 2005,
23:769-777.
50. Lee JH, Jeon MH, Seo YJ, Lee YJ, Ko JH, Tsujimoto Y, Lee JH: CA
repeats in the 3'-untranslated region of bcl-2 mRNA mediate
constitutive decay of bcl-2  mRNA.  J Biol Chem 2004,
279:42758-42764.
51. Khashnobish A, Hamann A, Osiewacz HD: Modulation of gene
expression by (CA)n microsatellites in the filamentous asco-
mycete Podospora anserina.  Appl Microbiol Biotechnol 1999,
52:191-195.
52. Martin-Farmer J, Janssen GR: A downstream CA repeat
sequence increases translation from leadered and unleadered
mRNA in Escherichia coli.  Mol Microbiol 1999, 31:1025-1038.
53. Hui J, Reither G, Bindereif A: Novel functional role of CA repeats
and hnRNP L in RNA stability.  RNA 2003, 9:931-936.
54. Ford GS, Barnhart B, Shone S, Covey LR: Regulation of CD154
(CD40 ligand) mRNA stability during T cell activation.  J
Immunol 1999, 162:4037-4044.
55. Anaya JM, Gomez L, Castiblanco J: Is there a common genetic
basis for autoimmune diseases?  Clin Dev Immunol 2006,
13:185-195.
56. Becker KG: The common genetic hypothesis of autoimmune/
inflammatory disease.  Curr Opin Allergy Clin Immunol 2001,
1:399-405.